Cong Huang - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
Carolina Ung - State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China
Haishaerjiang Wushouer - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
Lin Bai - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
Xinyi Li - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
Xiaodong Guan - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
Luwen Shi - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China

Background  In order to relieve the financial burden of the patients in China, the Ministry of Health (MoH) conducted the first national price negotiation and successfully negotiated three expensive medicines including ۲ targeted anticancer medicines (TAMs), icotinib and gefitinib. However, little evidence was available to demonstrate the impact of the national negotiation on TAMs use. The purpose of the study is to evaluate the implementation of the national price negotiation policy in China on TAMs use. Methods  We used interrupted time series (ITS) design to examine the changes in the daily cost, the monthly hospital purchasing volume and spending of icotinib and gefitinib with pharmaceutical procurement data from ۵۹۴ tertiary hospitals in ۲۹ provinces of mainland China between January ۲۰۱۵ and July ۲۰۱۷. The period between May and July ۲۰۱۶ was applied to assess the impact of policy.Results  The daily cost of icotinib and gefitinib decreased by ۵۰.۰۸% (P < .۰۰۱) and ۵۳.۸۹% (P < .۰۰۱) ۱۲ months after the national negotiation, respectively. In terms of volume, the negotiation was associated with increases in the trend of the monthly hospital purchasing volume of icotinib and gefitinib by ۴.۸۷ thousand defined daily doses (DDDs) (P < .۰۰۱) and ۶.۸۹ thousand DDDs (P < .۰۰۱). However, the monthly hospital purchasing spending of icotinib and gefitinib decreased rapidly by US۰.۵۱ million (P < .۰۱۰) and US۰.۸۲ million (P < .۰۵۰) following policy implementation, respectively. Conclusion  The first national negotiation had successfully cut off the price of two negotiated TAMs and promoted TAMs use in China. In the future, government should conduct further price negotiations and include more medicines with clinical benefits into reimbursement schemes to alleviate patients’ financial burden and promote their access to essential treatment.

Price Negotiation, Targeted Anticancer Medicines, Interrupted Time Series, China